EGFR Exon 20 insertion (A763_Y764insFQEA) mutant NSCLC is not identified by Roche Cobas Version 2 tissue testing but has durable intracranial and extracranial response to osimertinib
Affiliation
Lung Unit, The Royal Marsden Hospital, Chelsea, London, United Kingdom; Institute of Cancer Research, Sutton, London,Issue Date
2020
Metadata
Show full item recordAbstract
NoneCitation
Coleman N, Woolf D, Welsh L, McDonald F, MacMahon S, Yousaf N, et al. EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. J Thorac Oncol. 2020;15(10):e162-e5.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2020.05.006PubMed ID
32981603Additional Links
https://dx.doi.org/10.1016/j.jtho.2020.05.006Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2020.05.006
Scopus Count
Collections
Related articles
- Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
- Authors: Kunimasa K, Nishino K, Kukita Y, Matsumoto S, Kawachi H, Kawamura T, Inoue T, Tamiya M, Honma K, Sugimoto N, Yamasaki T, Imamura F, Goto K, Kumagai T
- Issue date: 2021 Aug
- Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
- Authors: Yang GJ, Li J, Xu HY, Sun Y, Liu L, Li HS, Yang L, Zhang Y, Li GH, Wang Y
- Issue date: 2021 Feb
- Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
- Authors: Hasegawa H, Yasuda H, Hamamoto J, Masuzawa K, Tani T, Nukaga S, Hirano T, Kobayashi K, Manabe T, Terai H, Ikemura S, Kawada I, Naoki K, Soejima K
- Issue date: 2019 Jan
- Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
- Authors: Lee Y, Kim TM, Kim DW, Kim S, Kim M, Keam B, Ku JL, Heo DS
- Issue date: 2019 Sep
- EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
- Authors: Fang W, Huang Y, Hong S, Zhang Z, Wang M, Gan J, Wang W, Guo H, Wang K, Zhang L
- Issue date: 2019 Jun 17